Title: Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy
Authors: Campone, Mario ×
Beck, J Thaddeus
Gnant, Michael
Neven, Patrick
Pritchard, Kathleen I
Bachelot, Thomas
Provencher, Louise
Rugo, Hope S
Piccart, Martine
Hortobagyi, Gabriel N
Nunzi, Martina
Heng, Daniel Y C
Baselga, José
Komorowski, Anna
Noguchi, Shinzaburo
Horiguchi, Jun
Bennett, Lee
Ziemiecki, Ryan
Zhang, Jie
Cahana, Ayelet
Taran, Tetiana
Sahmoud, Tarek
Burris, Howard A #
Issue Date: Nov-2013
Publisher: Clayton-Wray Publications Ltd.
Series Title: Current Medical Research and Opinion vol:29 issue:11 pages:1463-73
Article number: 10.1185/03007995.2013.836078
Abstract: Everolimus (EVE)+exemestane (EXE; n = 485) more than doubled median progression-free survival versus placebo (PBO) + EXE (n = 239), with a manageable safety profile and no deterioration in health-related quality-of-life (HRQOL) in patients with hormone-receptor-positive (HR(+)) advanced breast cancer (ABC) who recurred or progressed on/after nonsteroidal aromatase inhibitor (NSAI) therapy. To further evaluate EVE + EXE impact on disease burden, we conducted additional post-hoc analyses of patient-reported HRQOL.
ISSN: 0300-7995
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science